Tuberculosis, Multidrug-Resistant

Mechanisms of Resistance
Mycobacterium tuberculosis Subculture Results in Loss of Potentially Clinically Relevant Heteroresistance
John Z. Metcalfe, Elizabeth Streicher, Grant Theron, Rebecca E. Colman, Renee Penaloza, Christopher Allender, Darrin Lemmer, Robin M. Warren, David M. Engelthaler
Mechanisms of Action: Physiological Effects
Dual Mechanism of Action of 5-Nitro-1,10-Phenanthroline against Mycobacterium tuberculosis
Saqib Kidwai, Chan-Yong Park, Shradha Mawatwal, Prabhakar Tiwari, Myung Geun Jung, Tannu Priya Gosain, Pradeep Kumar, David Alland, Sandeep Kumar, Avinash Bajaj, Yun-Kyung Hwang, Chang Sik Song, Rohan Dhiman, Ill Young Lee, Ramandeep Singh
Clinical Therapeutics
Adverse Effects and Choice between the Injectable Agents Amikacin and Capreomycin in Multidrug-Resistant Tuberculosis
Amber Arnold, Graham S. Cooke, Onn Min Kon, Martin Dedicoat, Marc Lipman, Angela Loyse, Irina Chis Ster, Thomas S. Harrison
Open Access

Mechanisms of Resistance
A Novel 6-Benzyl Ether Benzoxaborole Is Active against Mycobacterium tuberculosisIn Vitro
Nipul Patel, Theresa O'Malley, Yong-Kang Zhang, Yi Xia, Bjorn Sunde, Lindsay Flint, Aaron Korkegian, Thomas R. Ioerger, Jim Sacchettini, M. R. K. Alley, Tanya Parish
Pharmacology
Sterilizing Effect of Ertapenem-Clavulanate in a Hollow-Fiber Model of Tuberculosis and Implications on Clinical Dosing
Sander P. van Rijn, Shashikant Srivastava, Mireille A. Wessels, Dick van Soolingen, Jan-Willem C. Alffenaar, Tawanda Gumbo
Mechanisms of Resistance
Impact of gyrB and eis Mutations in Improving Detection of Second-Line-Drug Resistance among Mycobacterium tuberculosis Isolates from Georgia
N. Bablishvili, N. Tukvadze, E. Shashkina, B. Mathema, N. R. Gandhi, H. M. Blumberg, R. R. Kempker
Open Access

Susceptibility
Pyrazinamide Susceptibility and pncA Mutation Profiles of Mycobacterium tuberculosis among Multidrug-Resistant Tuberculosis Patients in Bangladesh
Arfatur Rahman, Sara Sabrina Ferdous, Shahriar Ahmed, S. M. Mazidur Rahman, Mohammad Khaja Mafij Uddin, Suporn Pholwat, Jean Gratz, Eric Houpt, Sayera Banu
Pharmacology
Pharmacokinetics of Pyrazinamide and Optimal Dosing Regimens for Drug-Sensitive and -Resistant Tuberculosis
Maxwell T. Chirehwa, Helen McIlleron, Roxana Rustomjee, Thuli Mthiyane, Philip Onyebujoh, Peter Smith, Paolo Denti
Pharmacology
Lung Tissue Concentrations of Pyrazinamide among Patients with Drug-Resistant Pulmonary Tuberculosis
Russell R. Kempker, M. Tobias Heinrichs, Ketino Nikolaishvili, Irina Sabulua, Nino Bablishvili, Shota Gogishvili, Zaza Avaliani, Nestani Tukvadze, Brent Little, Adam Bernheim, Timothy D. Read, Jeannette Guarner, Hartmut Derendorf, Charles A. Peloquin, Henry M. Blumberg, Sergo Vashakidze
Letter to the Editor
Protecting Pyrazinamide, a Priority for Improving Outcomes in Multidrug-Resistant Tuberculosis Treatment
R. M. Anthony, M. Cynamon, S. Hoffner, J. Werngren, A. L. den Hertog, D. van Soolingen

Main menu

User menu

Search

Tuberculosis, Multidrug-Resistant

Pages